HK1203044A1 - Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders cns - Google Patents
Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders cnsInfo
- Publication number
- HK1203044A1 HK1203044A1 HK15102094.4A HK15102094A HK1203044A1 HK 1203044 A1 HK1203044 A1 HK 1203044A1 HK 15102094 A HK15102094 A HK 15102094A HK 1203044 A1 HK1203044 A1 HK 1203044A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cns
- necrostatins
- alone
- compositions
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550191P | 2011-10-21 | 2011-10-21 | |
PCT/US2012/061324 WO2013059791A2 (en) | 2011-10-21 | 2012-10-22 | Methods and compositions for promoting axon regeneration and nerve function |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203044A1 true HK1203044A1 (en) | 2015-10-16 |
Family
ID=47116494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102094.4A HK1203044A1 (en) | 2011-10-21 | 2015-03-02 | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders cns |
Country Status (6)
Country | Link |
---|---|
US (3) | US20140357570A1 (ja) |
EP (1) | EP2773341A2 (ja) |
JP (3) | JP6254090B2 (ja) |
CA (1) | CA2888805C (ja) |
HK (1) | HK1203044A1 (ja) |
WO (1) | WO2013059791A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011242465B2 (en) | 2010-04-23 | 2017-01-19 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
WO2012061045A2 (en) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving retinal ganglion cells |
US20140357570A1 (en) | 2011-10-21 | 2014-12-04 | Massachusetts Eye And Ear Infirmary | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders |
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
CL2013003785A1 (es) * | 2013-12-30 | 2014-07-11 | Univ Pontificia Catolica Chile | Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos |
TW201632516A (zh) | 2014-12-11 | 2016-09-16 | 哈佛大學校長及研究員協會 | 細胞壞死抑制劑與相關方法 |
US20180044375A1 (en) | 2015-03-06 | 2018-02-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
CR20180413A (es) | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
KR20200118422A (ko) * | 2017-12-31 | 2020-10-15 | 에버그린 바이오사이언시즈 | 동결보존용 조성물 및 이의 사용 방법 |
WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
RU2749634C1 (ru) * | 2020-11-30 | 2021-06-16 | Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации | Способ моделирования лечения больных с двигательными и висцеральными расстройствами на лабораторных животных. |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
ATE414149T1 (de) | 1996-11-20 | 2008-11-15 | Univ Yale | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
EP1154691A4 (en) | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | TARGETED ADMINISTRATION OF REGULATED RELEASE MEDICINE TO RETINA AND CHOROID THROUGH SCLEROTIC |
WO2001028493A2 (en) * | 1999-10-15 | 2001-04-26 | President And Fellows Of Harvard College | Small molecule inhibitors of necrosis |
WO2001028472A1 (en) | 1999-10-21 | 2001-04-26 | Alcon Universal Ltd. | Drug delivery device |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
AU1920501A (en) | 1999-12-03 | 2001-06-12 | Alcon Universal Limited | The use of caspase 9 inhibitors to treat ocular neural pathology |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
WO2002063959A1 (en) * | 2001-02-09 | 2002-08-22 | The Schepens Eye Research Institute | Methods and compositions for stimulating axon regeneration and prventing neuronal cell degeneration |
WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
AU2003209297A1 (en) | 2002-01-18 | 2003-09-02 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20050130877A1 (en) * | 2003-03-14 | 2005-06-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitors |
ES2567135T3 (es) * | 2003-08-29 | 2016-04-20 | The Brigham And Women's Hospital, Inc. | Derivados de hidantoína como inhibidores de necrosis celular |
US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
US20070298129A1 (en) | 2005-08-24 | 2007-12-27 | Neurotech Pharmaceuticals Co., Ltd. | Compounds and compositions for treating neuronal death or neurological dysfunction |
US20070049565A1 (en) * | 2005-08-24 | 2007-03-01 | Neurotech Pharmaceuticals Co., Ltd. | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction |
EP1968583A4 (en) * | 2005-12-20 | 2010-09-15 | Harvard College | COMPOUNDS, TESTS AND METHODS OF TREATMENT |
WO2007071448A2 (en) | 2005-12-23 | 2007-06-28 | Partnership & Corp. Technology Transfer | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
EP2076134A4 (en) | 2006-10-10 | 2020-07-29 | President and Fellows of Harvard College | CONNECTIONS, SCREENS AND TREATMENT METHODS THEREFOR |
US20090022570A1 (en) * | 2007-07-16 | 2009-01-22 | Joe David Craig | System, method and apparatus for feeding biomass into a pressurized vessel |
EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
WO2010075290A1 (en) | 2008-12-22 | 2010-07-01 | President And Fellows Of Harvard College | Unsaturated heterocyclic inhibitors of necroptosis |
US7622106B1 (en) | 2009-03-06 | 2009-11-24 | Board Of Regents, The University Of Texas System | Necrosis assay |
WO2011071088A1 (ja) | 2009-12-09 | 2011-06-16 | 北海道公立大学法人 札幌医科大学 | スーパーオキシド製造方法、スーパーオキシド消去能評価方法、スーパーオキシド製造装置およびスーパーオキシド消去能評価装置 |
AU2011242465B2 (en) | 2010-04-23 | 2017-01-19 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
WO2012061045A2 (en) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving retinal ganglion cells |
US20140357570A1 (en) | 2011-10-21 | 2014-12-04 | Massachusetts Eye And Ear Infirmary | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders |
-
2012
- 2012-10-22 US US14/352,960 patent/US20140357570A1/en not_active Abandoned
- 2012-10-22 CA CA2888805A patent/CA2888805C/en active Active
- 2012-10-22 JP JP2014537360A patent/JP6254090B2/ja active Active
- 2012-10-22 WO PCT/US2012/061324 patent/WO2013059791A2/en active Application Filing
- 2012-10-22 EP EP12780381.5A patent/EP2773341A2/en not_active Withdrawn
-
2015
- 2015-03-02 HK HK15102094.4A patent/HK1203044A1/xx unknown
- 2015-11-02 US US14/930,501 patent/US10022419B2/en active Active
-
2017
- 2017-11-29 JP JP2017228601A patent/JP6560325B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-22 US US16/015,947 patent/US10799552B2/en active Active
-
2019
- 2019-07-18 JP JP2019132740A patent/JP6861764B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013059791A2 (en) | 2013-04-25 |
US20140357570A1 (en) | 2014-12-04 |
CA2888805A1 (en) | 2013-04-25 |
JP6560325B2 (ja) | 2019-08-14 |
CA2888805C (en) | 2020-07-14 |
WO2013059791A3 (en) | 2013-07-11 |
JP2018065838A (ja) | 2018-04-26 |
US10799552B2 (en) | 2020-10-13 |
EP2773341A2 (en) | 2014-09-10 |
US10022419B2 (en) | 2018-07-17 |
JP6254090B2 (ja) | 2017-12-27 |
US20160151442A1 (en) | 2016-06-02 |
JP2019196381A (ja) | 2019-11-14 |
JP6861764B2 (ja) | 2021-04-21 |
US20190117724A1 (en) | 2019-04-25 |
JP2014530881A (ja) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203044A1 (en) | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders cns | |
IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
HK1252940A1 (zh) | 用於治療無效性紅細胞生成的方法和組合物 | |
EP2875359A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES | |
HK1201475A1 (en) | Methods and compositions for treating pain | |
WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
EP2900835A4 (en) | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS | |
EP2812452A4 (en) | METHOD AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENT DISORDERS | |
WO2012062925A3 (en) | Compounds and methods for treating pain | |
EP2766483A4 (en) | METHOD AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENT DISORDERS | |
EP2429530A4 (en) | METHOD AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC ILLNESSES | |
EP2914335A4 (en) | COMPOSITIONS, STRUCTURES AND METHODS OF NERVE REGENERATION | |
EP2523553A4 (en) | METHOD AND COMPOSITIONS FOR TREATING BLOOD DISORDER | |
HK1213912A1 (zh) | 用於治療多發性硬化及相關病症的方法和組合物 | |
EP2903619A4 (en) | PHOSPHODIESTERASE INHIBITORS FOR TREATING TASTE AND ODORAT DISORDERS | |
EP2550361A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDER | |
IL231787A (en) | History of uridine diphosphate, their preparations and their use in the treatment of neurodegenerative diseases | |
HK1199831A1 (en) | Composition for improving and or treating central nervous system degenerative disease | |
IL232710B (en) | l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders | |
EP2989123A4 (en) | METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS | |
EP2911660A4 (en) | COMPOSITIONS AND METHODS FOR TREATING STROGEN-RELATED MEDICAL DISORDERS | |
EP2912033A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES | |
AP2013007056A0 (en) | Methods and compositions for treating kidney disorders | |
ZA201206898B (en) | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders | |
WO2013106460A3 (en) | Compositions and methods for treating malignant astrocytomas |